It is very strange that Traboulsee et al.1 did not publish any MRI data; this does not allow a meta-analysis comparison with other trials. The Brave Dreams trial2 examined patients with relapsing-remitting MS (RRMS) undergoing percutaneous transluminal angioplasty (PTA) for chronic cerebrospinal venous insufficiency, and this Canadian study contains a mixed population of RRMS and secondary-progressive MS.1 Furthermore, a population with a mean age of 50 years and a disease duration of 17 years is not an acceptable study group for PTA

Source link